EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Peijia Medical's enterprise value is HK$1,691.8 Mil.
Peijia Medical's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was HK$482.5 Mil. Therefore, Peijia Medical's EV-to-Revenue for today is 3.51.
The historical rank and industry rank for Peijia Medical's EV-to-Revenue or its related term are showing as below:
HKSE:09996'
s EV-to-Revenue Range Over the Past 10 Years
Min: 2.38 Med: 20.07 Max: 1004.37
Current: 3.51
During the past 6 years, the highest EV-to-Revenue of Peijia Medical was 1004.37. The lowest was 2.38. And the median was 20.07.
HKSE:09996's EV-to-Revenue is ranked worse than 52.41% of 830
companies
in the Medical Devices & Instruments industry
Industry Median: 3.24
vs HKSE:09996: 3.51
As of today (2024-05-23), Peijia Medical's stock price is HK$3.66.
Peijia Medical's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was HK$0.71. Therefore, Peijia Medical's PS Ratio for today is 5.15.
Peijia Medical EV-to-Revenue Historical Data
The historical data trend for Peijia Medical's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Peijia Medical's EV-to-Revenue
For the Medical Devices subindustry, Peijia Medical's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Peijia Medical's EV-to-Revenue Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Peijia Medical's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Peijia Medical's EV-to-Revenue falls into.
Peijia Medical's current Enterprise Value is HK$1,691.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Peijia Medical's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was HK$482.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Peijia Medical (HKSE:09996) EV-to-Revenue Explanation
Peijia Medical's share price for today is HK$3.66.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Jun. 2023 was HK$0.71.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Peijia Medical EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Peijia Medical's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Peijia Medical Ltd is focused on the interventional procedural, transcatheter valve therapeutic, and the neurointerventional procedural medical device market in China. The company's product candidates include Transcatheter Aortic Valve Replacement products, Transcatheter Mitral Valve Replacement/Transcatheter Tricuspid Valve Replacement products, Ancillary products, Neurointerventional products, and its product pipeline consists of transcatheter valve therapeutic and neurointerventional products and product candidates. Its operating segments are Transcatheter Valve Therapeutic Business and Neurointerventional Business.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:09996 has been successfully added to your 